Toll Free: 1-888-928-9744

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals

Published: Apr 1, 2016 | Pages: 104 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals

Summary

GlobalData's 
 Table of Contents
1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 9 2 Pharmaceuticals & Healthcare, Global, Deal Summary 12 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2016 12 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, February 2016 14 2.2.1 Mylan to Acquire Meda for USD9.9 Billion 14 2.2.2 GTCR to Form Joint Venture with Ed Fiorentino 16 2.2.3 Baxalta Enters into Agreement with Precision Biosciences 16 2.2.4 McKesson to Acquire Vantage Oncology and Biologics for USD1.2 Billion 17 2.2.5 Ipsen Enters into Licensing Agreement with Exelixis 17 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2016 19 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2016 20 3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 21 3.1 Pharmaceuticals & Healthcare, Global, M&A, February 2016 21 3.1.1 Top M&A Deals in February 2016 22 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2015 - February 2016 23 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2016 25 3.2.1 Top Equity Offering Deals in February 2016 26 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2015 - February 2016 27 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2016 29 3.3.1 Top PE/VC Deals in February 2016 30 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2016 31 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2016 33 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, September 2015-February 2016 35 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2015-February 2016 36 4 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2016 37 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2016 37 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2015 - February 2016 39 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2016 41 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2016 42 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 43 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2015 - February 2016 45 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2015 - February 2016 46 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 48 5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2016 50 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2016 50 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 52 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2015 - February 2016 54 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2015 - February 2016 56 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2015 - February 2016 58 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2015 - February 2016 61 5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2016 62 5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2016 63 5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2016 63 6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 64 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2016 64 6.1.1 Oncology - Deals of the Month 66 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2016 68 6.2.1 Central Nervous System - Deals of the Month 70 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2016 71 6.3.1 Infectious Diseases - Deals of the Month 73 6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2016 74 6.4.1 Cardiovascular - Deals of the Month 76 6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2016 77 6.5.1 Immunology - Deals of the Month 78 6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, February 2016 79 6.6.1 Gastrointestinal - Deal of the Month 81 6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, February 2016 82 6.7.1 Metabolic Disorders - Deal of the Month 83 7 Deal Summary by Geography 84 7.1 Pharmaceuticals & Healthcare, North America Deals, February 2016 84 7.1.1 North America - Deals of the Month 86 7.2 Pharmaceuticals & Healthcare, Europe, Deals, February 2016 88 7.2.1 Europe - Deals of the Month 90 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2016 92 7.3.1 Asia-Pacific - Deals of the Month 93 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2016 95 7.4.1 Rest of the World - Deals of the Month 96 8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 97 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2015 - February 2016 97 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2015 - February 2016 99 9 Further Information 101 9.1 Methodology 101 9.2 About GlobalData 102 9.3 Disclosure information 102 9.4 Disclaimer 103
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 13 Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, February 2016 14 Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2016 20 Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 22 Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2016 22 Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2015 - February 2016 24 Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 26 Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2016 26 Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 28 Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 30 Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2016 30 Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2015 - February 2016 32 Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 2016 34 Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 36 Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2015 - February 2016 36 Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 38 Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 40 Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 42 Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 42 Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 44 Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2015 - February 2016 47 Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2015 - February 2016 49 Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 51 Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 53 Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 55 Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2016 57 Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2015 - February 2016 60 Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2016 62 Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 2016 62 Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2016 63 Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2016 63 Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 65 Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 69 Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 72 Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 75 Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 78 Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 80 Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 83 Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 85 Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 89 Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 93 Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 96 Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 98 Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 100


List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 12 Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), February 2016 19 Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 2016 20 Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 21 Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2015 - February 2016 23 Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 25 Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 27 Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 29 Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2015 - February 2016 31 Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 2016 33 Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), February 2016 34 Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 35 Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 37 Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 39 Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 41 Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 43 Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2015 - February 2016 45 Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2015 - February 2016 46 Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 48 Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 50 Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 52 Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 54 Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 - February 2016 56 Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, September 2015 - February 2016 58 Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), September 2015 - February 2016 59 Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2016 61 Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 64 Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 68 Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 71 Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 74 Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 77 Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 79 Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 82 Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 84 Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 88 Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 92 Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 95 Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 97 Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2015 - February 2016 99

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...
Choose License Type
Single User - US $1000
Multi User - US $2000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify